Cryopyrin-Associated Periodic Syndrome Medication Savings with TheDrugClub
Discount pricing may be available. Current formulary eligibility is being verified; a condition association does not establish FREE coverage.
- Join TheDrugClub as a member
- Receive your member card by email
- Present your card at a participating pharmacy
- Check active-formulary eligibility or available discount pricing
About Cryopyrin-Associated Periodic Syndrome
Cryopyrin-Associated Periodic Syndrome (CAPS) is a group of rare genetic inflammatory disorders causing recurrent fevers, rashes, and joint pain. Managing CAPS often requires specialized, high-cost medications. TheDrugClub offers a vital solution, helping members significantly reduce the cost of these essential prescriptions, ensuring access to the care you need without financial strain.
Cryopyrin-Associated Periodic Syndrome (CAPS) refers to a spectrum of inherited autoinflammatory diseases, including Familial Cold Autoinflammatory Syndrome (FCAS), Muckle-Wells Syndrome (MWS), and Chronic Infantile Neurological, Cutaneous, and Articular Syndrome (CINCA), also known as Neonatal-Onset Multisystem Inflammatory Disease (NOMID). These conditions are caused by mutations in the *NLRP3* gene, which leads to an overproduction of a key inflammatory protein called interleukin-1 beta (IL-1β).
Individuals with CAPS experience recurrent episodes of inflammation, often triggered by cold exposure in FCAS, but otherwise appearing spontaneously. Common symptoms across the spectrum include recurring fevers, a characteristic urticarial-like rash, and joint pain or swelling. More severe forms, like MWS and CINCA/NOMID, can involve chronic fatigue, eye inflammation, hearing loss, and neurological complications such as chronic aseptic meningitis and developmental delays. If left untreated, CAPS can lead to serious long-term damage, including kidney failure due to amyloidosis.
Treatment for CAPS primarily focuses on targeting the overactive IL-1β pathway. The most common and effective medications are IL-1 inhibitors, which are biologic drugs designed to block the action of IL-1β. These include:
- Anakinra (Kineret): An IL-1 receptor antagonist, typically administered daily by injection.
- Canakinumab (Ilaris): A monoclonal antibody that directly binds to IL-1β, usually given every 4-8 weeks by injection.
- Rilonacept (Arcalyst): An IL-
The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.